Illustration of the supply chain for targeted alpha therapy in Japan using Astatine-211. The graphic shows domestic cyclotron production, GMP radiochemistry and automated purification, a national site network strategy, time-critical logistics across Japan due to the 7.2-hour half-life, and outpatient administration of the radiopharmaceutical.
Radioligand therapy is now a board-level topic in Japan, not because the science is new, but […]
Japan’s IVD sector remains highly structured and closely governed, benefiting from a mature healthcare infrastructure and […]
Speaker presenting at the launch event of TOBU on-demand biobank in Japan.
Some of Japan’s most forward-thinking minds gathered to scrutinise Japan’s biobank conundrum at Shonan iPark. In […]
Our CEO Stefan Sandström at the MedicalJapan 2023 event at Makuhari Messe in Chiba.
Venturing into the heart of Medical Japan at Makuhari Messe was an exhilarating experience. Although situated […]